Sorry!! The article you are trying to read is not available now.

Minyanville

All Biotech/pharma Articles

Get FREE MINYANVILLE
Newsletters & Alerts

Four Closely Watched Drug Decisions Loom in February

By Brett Chase Jan 31, 2013 2:45 pm

The month also features a big gathering of biotech CEOs in New York and a cancer research meeting in Florida. Read this article

Celsion Shares Nosedive After Cancer Therapy Fails

Brett Chase

Isis and Sanofi's Drug OK'd to Treat Inherited Cholesterol Disease

Brett Chase

Keryx Biopharmaceuticals Surges on Prospects for Kidney Drug

Brett Chase

Threshold Pharmaceuticals Rises on Hope for Cancer Drug

Brett Chase

Biogen Idec Aims to Preserve MS Drug Avonex's Sales

Brett Chase

Impax Laboratories' Parkinson's Drug Rejected by FDA

Brett Chase

NuPathe Shares Jump After US Approves Migraine Patch

Brett Chase

GlaxoSmithKline Aims to Compete in Packed Field of Diabetes Drugs

Brett Chase

Johnson & Johnson Diabetes Drug Endorsed by Review Panel

Brett Chase

Teva Aims to Derail Approval of Biogen Idec's MS Pill

Brett Chase

Idenix Says FDA Needs More Time to Review Hold on Hepatitis C Drug

Brett Chase

Johnson & Johnson Diabetes Medicine Faces Big Test

Brett Chase

Celgene Rises After CEO Hugin Touts New Drugs, Sales Growth

Brett Chase

Which Abbott Shares Should You Keep?

MoneyShow.com

X Factor: 5 Stocks Reaching Their Ex-Dividend Date on January 11

Christopher Witrak

Biogen Idec's Drug for Rare Disease Fails in Study

Brett Chase

Biogen and PowerShares QQQ Trust Among Most Active Stocks in Nasdaq Pre-Market

Christopher Witrak

Recommendations

Archive

TICKERS

PFE

MRK

JNJ

BMY

GSK

DNDN

GILD

VRTX

AMGN

LLY

ARNA

BIIB

See All Tickers »